- Info
- Significant Ownership
- Insider Trading
- Financials
- Holders: AZN, AZN
Significant Ownership of ASTRAZENECA PLC
- Signature - Title
- /s/ Matthew Bowden - Matthew Bowden / Company Secretary
- Location
- Cambridge
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by ASTRAZENECA PLC.
Follow Filing Activity
Follow ASTRAZENECA PLC and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of ASTRAZENECA PLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CLLS | Cellectis S.A. | Ordinary shares, nominal value of EUR0.05 per ordinary share | 44% | $66,440,000 | 44,000,000 | AstraZeneca PLC | 23 Jan 2025 | ||
| Innate Pharma SA | Ordinary Shares, EUR0.05 nominal value per share | 8.3% | 7,825,501 | AstraZeneca PLC | 22 Dec 2025 | ||||
| MNPR | Monopar Therapeutics Inc. | Common Stock, $0.001 par value per share | 7.8% | $34,126,392 | 522,667 | AstraZeneca PLC | 31 Dec 2025 | ||
| CDT | Conduit Pharmaceuticals Inc. | Common Stock, par value $0.0001 per share | 1.1% | $3,340 | 73,892 | AstraZeneca PLC | 31 Mar 2025 |
Schedules 13D/G Reported by ASTRAZENECA PLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.